BACKGROUND: Breast cancer is the most common malignant neoplasm in the female population. However, stomach is a rare site for metastasis, and can show up many years after initial diagnosis and treatment of the primary tumor. AIM: Analyze a case series of this tumor and propose measures that can diagnose it with more precocity. METHODS: Were analyzed 12 patients with secondary gastric tumors. Immunohistochemistry has demonstrated that primary tumor was breast cancer. We retrieved information of age, histological type, interval between diagnosis of the primary breast cancer and its metastases, immunohistochemistry results, treatment and survival. RESULTS: The mean age was 71.3 years (ranging 40-86). Ten cases had already been underwent mastectomy in the moment of the diagnosis of gastric metastasis. Two patients had diagnosis of both primary and secondary tumors concomitantly. At average, diagnosis of gastric metastasis was seven years after diagnosis of primary breast cancer (ranging 0-13). Besides, nine cases had also metastases in other organs, being bones the most affected ones. Immunohistochemistry of the metastases has shown positivity for CK7 antibody in 83.34%, estrogen receptor in 91.67%, progesterone receptor in 66.67% and AE1AE3 antibody in 75%, considering all 12 cases. Moreover, CK20 was absent significantly (66.67%). The positivity of BRST2 marker did not present statistical significance (41.67%). Eight cases were treated with chemotherapy associated or not with hormonal blockade. Surgical treatment of gastric metastasis was performed in four cases: three of them with total gastrectomy and one with distal gastrectomy. Follow-up has shown a mean survival of 14.58 months after diagnosis of metastasis, with only two patients still alive. CONCLUSION: Patients with a history of breast cancer presenting endoscopic diagnosis of gastric cancer it is necessary to consider the possibility of gastric metastasis of breast cancer. The confirmation is by immunohistochemistry and gastrectomy should be oriented in the absence of other secondary involvement and control of the primary lesion.
BACKGROUND:Breast cancer is the most common malignant neoplasm in the female population. However, stomach is a rare site for metastasis, and can show up many years after initial diagnosis and treatment of the primary tumor. AIM: Analyze a case series of this tumor and propose measures that can diagnose it with more precocity. METHODS: Were analyzed 12 patients with secondary gastric tumors. Immunohistochemistry has demonstrated that primary tumor was breast cancer. We retrieved information of age, histological type, interval between diagnosis of the primary breast cancer and its metastases, immunohistochemistry results, treatment and survival. RESULTS: The mean age was 71.3 years (ranging 40-86). Ten cases had already been underwent mastectomy in the moment of the diagnosis of gastric metastasis. Two patients had diagnosis of both primary and secondary tumors concomitantly. At average, diagnosis of gastric metastasis was seven years after diagnosis of primary breast cancer (ranging 0-13). Besides, nine cases had also metastases in other organs, being bones the most affected ones. Immunohistochemistry of the metastases has shown positivity for CK7 antibody in 83.34%, estrogen receptor in 91.67%, progesterone receptor in 66.67% and AE1AE3 antibody in 75%, considering all 12 cases. Moreover, CK20 was absent significantly (66.67%). The positivity of BRST2 marker did not present statistical significance (41.67%). Eight cases were treated with chemotherapy associated or not with hormonal blockade. Surgical treatment of gastric metastasis was performed in four cases: three of them with total gastrectomy and one with distal gastrectomy. Follow-up has shown a mean survival of 14.58 months after diagnosis of metastasis, with only two patients still alive. CONCLUSION:Patients with a history of breast cancer presenting endoscopic diagnosis of gastric cancer it is necessary to consider the possibility of gastric metastasis of breast cancer. The confirmation is by immunohistochemistry and gastrectomy should be oriented in the absence of other secondary involvement and control of the primary lesion.
Breast cancer is the most common malignant tumor in the female population, accounting
for high morbidity and mortality worldwide. In addition, metastases of breast cancer
usually are directed to bones, lung, liver and brain. However, metastases to the stomach
are very unusual and there are a few studies on this subject
,
,
,
,
,
,
,
,
. When these metastases occur, diagnostic confirmation based on
immunohistochemistry is needed
,
,
,
,
,
,
,
.Considering that there are a few number of cases described in the medical literature,
this paper aims to report a case series, helping to improve knowledge concerning this
uncommon breast cancer metastasis.
METHODS
This study is a non-randomized retrospective review of 12 patients with breast cancer
metastasis in their stomachs that were treated from 2001 to 2011.Were reviewed the medical records and features considered were: age, histology, time gap
between diagnosis of the primary tumor and its metastasis, hormonal receptors,
histological markers BRST2, CK7, RE, RP, CK20, HER2, others organs with metastasis,
upper endoscopy findings, computerized tomography scan findings, treatment and
follow-up.A pathologist with breast cancer expertise provided data concerning histology and
immunohistochemistry. Besides, treatment employed was according to guidelines
established by the Brazil Ministry of Health and by the World Health Organization.Global survival was the time gap between metastasis diagnoses until death caused by any
reason. The follow-up was until March 2015, when this study ended.A level of significance of 5% (p<0.05) was adopted.
RESULTS
Patients in the moment of the diagnoses of the gastric metastasis were 40 to 86 years
old (mean 71.3). Ten of twelve patients had been submitted to mastectomy previously and
two of them had the diagnoses of gastric metastasis concomitantly with the diagnoses of
the primary tumor. Thus, the time gap between primary tumor and metastasis diagnoses
ranged from 0 to 13 years (average 6.75).Ten of twelve patients with metastasis in the stomach had other organs involved at the
same moment, being bones the most affected ones (nine of 12 cases, 75%). After bone
involvement, were observed metastases in lungs (3/12 cases, 25%), large bowel (n=1),
liver (n=1), esophagus (n=2), mediastinum (n=1) and skin (n=1).The predominating symptoms were nausea and vomiting (n=5, 41.6%), weight loss (n=4,
33.3%), upper abdominal pain (n=3, 25%), gastric emptying impaired (16.6%) and dyspepsia
(n=1, 8.3%).Histology of the primary tumor consisted of lobular pattern in five cases (41.6%) and
ductal pattern in seven (58.3%). There was not a higher mortality linked to any pattern
(p=0.813).Considering hormonal receptors, estrogen receptor was present in 11 cases (91.6%) and
progesterone receptor in six (66.6%). However, estrogen receptor was searched in all
cases and progesterone receptor was searched in only nine.Considering antibodies, CK20 monoclonal antibody was absent in eight of nine cases
(88.8%), CK7 antibody was present in 10 of 11 cases (90.9%), BRST2 antibody was present
in only five (41.6%) although BRST2 antibody was searched in all 12 cases. None of these
markers has shown an increase in mortality (p>0.05%). Finally, HER2 was searched in
only three cases, being positive in two (66.6%).Concerning treatment, eight cases received chemotherapy associated or not with hormonal
blockade. Four had their metastasis in the stomach treated surgically, three of them
submitted to total gastrectomy and one to distal gastrectomy. The gastrectomies were
associated to a D2 level lymphadenectomy (Figures 1
and 2).
FIGURE 1
Upper endoscopy showing breast cancer metastasis to the stomach and
surgical specimens showing breast cancer metastasis to the stomach like
linitis
Mean survival after the diagnoses of metastasis in the stomach was only 14.58 months.
However, mean survival increases to 38 months when considering only the four patients
treated surgically.
DISCUSSION
Prevalence of metastasis of a primary breast cancer to the digestive tract is rare,
being calculated an occurrence of non-greater than 0.3% in the stomach resections.
Nonetheless, studies of necropsies observed this uncommon event in patients with a
breast cancer history ranging from 4% to 35%. Furthermore, 94% of these patients had
other organs affected concomitantly
,
,
.Some authors report an average time between primary tumor diagnoses and metastasis to
the stomach ranging from 4 to 10 years 3,6,. The mean age of these metastatic
tumors is predominantly in the perimenopausal period due to hormonal imbalances typical
of this phase
.The most common aspect of presentation of these metastases in the stomach is linitis,
affecting muscle layer and submucosae at maximum rate of 73% of cases
,
,
,
,
.According to some authors, lobular carcinoma is the most common source of metastases to
the stomach at a maximum rate of 83% of the cases
,
,
. In addition, even when mix ductal-lobular carcinomas are present, it is
observed a predominant component of lobular carcinoma of the metastases to the digestive
tract
,
.Besides, medical literature presents us that the most frequent symptoms are dyspepsia,
loss of appetite, upper abdominal pain, nausea, vomiting and gastric emptying impaired
,
,
,
. Nonetheless, these symptoms lack any specificity considering that patients
usually are receiving chemotherapy, radiotherapy or even suffering of electrolytic
disorders. Because of that, there could be a delay in diagnoses
.Subsidiary examinations like upper endoscopy, computerized tomography scans or positron
emission tomography must be part of the diagnostic effort. However, they have lower
specificity
,
,
,
,
,
.Finally, immunohistochemistry searching for hormonal receptors (estrogen and
progesterone) show a higher rate of diagnostic evidence
,
.According to medical literature, Gross cystic disease fluid protein-15 monoclonal
antibody (GCDFP-15) or BRST2 has shown sensibility of 55-76% and specificity of 95-100%
for the diagnosis of metastatic breast cancer
,
,
. The CK7 monoclonal antibody is present in tumors with glandular pattern, being
observed at a maximum rate of 90% of breast cancers. It suggests breast cancer
metastasis considering that only 50-64% of adenocarcinomas of the stomach present this
molecule
,
,
. On the other hand, CK20 antibody presence favors the diagnoses of primary
cancers from stomach, large bowel and pancreas
,
,
,
,
. In this study, was verified an endorsement of this immunohistochemistry profile
that means positivity for estrogen receptor, progesterone receptor and CK7 antibody and
negativity for CK20 antibody.HER2 marker is present in about 15% to 20% of cases of breast cancer. Although it is not
useful for diagnoses when used as an isolated marker because it is also common in
primary gastric cancer, its presence infers a greater aggressiveness and a worst
prognosis of the disease
,
.There is a consensus in the literature that first line therapy for breast cancer
metastasis to the stomach is chemotherapy associated or not with hormonal blockade
,
,
,
,
. Mean survival after diagnoses of breast cancer metastasis to the stomach was of
seven months (0 to 41 months) in the absence of complications
,
.Despite the publications showing increase in survival of patients submitted to
metastasis resection of liver and of the lung, there are not studies with significant
evidence of these same results when metastasis is in the digestive tract
. However, if there is an isolated metastasis in the stomach and, concomitantly,
primary tumor is controlled, it is possible to achieve an increase in survival from nine
months to 44 months when gastric resection is performed
,
,
,
. In this study, when was considered survival of patients submitted to gastric
resection, was found out a 38 months survival, much better of the 14.38 months survival
of the whole group.Finally, gastric adenocarcinoma has a high incidence in the population, being more
frequent in males
. However, female with a history of previous treatment and surgery for breast
tumor, it is important to research the association and the occurrence of metastasis
gastric.
CONCLUSION
In patients with a previous history of breast cancer showing an endoscopic tumor in the
stomach, should be considered the possibility of breast cancer metastasis. Moreover,
after diagnosis of a breast cancer metastasis to the stomach, surgical resection should
be indicated considering primary tumor control and absence of involvement of other
organs.
Authors: D Pectasides; A Psyrri; K Pliarchopoulou; T Floros; G Papaxoinis; M Skondra; G Papatsibas; A Macheras; G Athanasas; P Arapantoni-Datioti; T Economopoulos Journal: Anticancer Res Date: 2009-11 Impact factor: 2.480
Authors: Gregory E Jones; Dirk C Strauss; Matthew J Forshaw; Harriet Deere; Ula Mahedeva; Robert C Mason Journal: World J Surg Oncol Date: 2007-07-09 Impact factor: 2.754
Authors: William A Nehmeh; Joseph Derienne; Léa El Khoury; Serge Kassar; Viviane Track-Smayra; Roger Noun; Ghassan Chakhtoura Journal: Am J Case Rep Date: 2021-04-08